Attached files
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment No. 1 to Registration Statement on Form S-1 (No. 333-255132) of our report dated February 26, 2021, (April 26, 2021, as to the effects of the reverse stock split described in Note 16) relating to the financial statements of Werewolf Therapeutics, Inc. We also consent to the reference to us under the heading Experts in such Registration Statement.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
April 26, 2021